KRAS and brain neoplasm: The frequency of mutations in the genes is consistent with that reported in the literature for IDH1 and IDH2 in brain tumors [1,32], EGFR and KRAS in NSCLCs [1,4,12,34,37], KRAS and NRAS in CRCs [1,4], BRAF [37,38,42], RAS, PIK3CA, and TERT in thyroid nodules [1,18,39,42], BRAF, NRAS and cKIT in melanoma [1,4], and KRAS in pancreatic pre-operative samples [1,25,35].